ONE LEVEL DEEPER
DXCM
Warren Buffett frameworkThe Owner-OperatorBenjamin Graham frameworkThe Value ArchitectMichael Mauboussin frameworkThe Expectations EngineerHoward Marks frameworkThe Cycle WhispererPeter Lynch frameworkThe Everyday Edge

4.2% revenue growth meets 24x earnings — Lynch framework sees a fast grower's valuation on a stalwart's growth rate.

cautiousLeaning Bearishconviction

A fast grower stumbling into maturity — revenue decelerates to 4.2% while margins expand to record 25.6%, creating a valuation puzzle Lynch would find uncomfortable.

THE LENSES
THE CLASSIFICATIONtransitioning

Is this a fast grower, stalwart, or something else?

Revenue growth slowed from 15.6% TTM to 4.2% in Q4'25
Operating margin expanded to record 25.6% in Q4'25
Free cash flow generation of $1.08B TTM supports aggressive buybacks
Healthcare device company serving diabetes management market

This framework sees a fast grower losing its speed — the 4.2% quarterly growth suggests a transition to stalwart territory. The expanding margins indicate operational excellence, but Lynch valued growth over efficiency.

Revenue
THE GROWTH STORYclear

Can you explain the growth in one simple sentence?

DexCom makes continuous glucose monitors for diabetes patients
Expanding from type 1 to type 2 diabetes and consumer health with Stelo product
100% international revenue concentration in FY2025 data suggests data incompleteness
Revenue shows 0.981 correlation with inflation, indicating pricing power

The growth story is clear — "they make devices that help diabetics monitor glucose continuously" — but execution is slowing. Market expansion into type 2 diabetes represents the remaining growth opportunity, though current 4.2% growth suggests limited runway.

Operating Income
THE PEG RATIOexpensive

Are you paying a fair price for the growth you're getting?

P/E ratio of 24.0 with EPS growth visible in recent quarters
Revenue growth decelerated from 15.6% TTM to 4.2% Q4'25
Market implies 6.09% perpetual growth in DCF analysis
Earnings yield of 1.04% versus 4.33% treasury rate

Applying this lens shows concerning math — if growth is 4.2%, the PEG exceeds 5.7, far above Lynch's comfort zone of 1.0. Even using the implied 6.09% growth rate yields a PEG near 4.0, suggesting significant overvaluation for the growth available.

P/E Ratio
WHERE IN THE STORYlate

Are we in the early, middle, or late innings of this growth story?

Revenue growth decelerated from 15.6% TTM to 4.2% in Q4'25
Operating margins hit record 25.6%, suggesting optimization phase
ROIC reached all-time high of 6.01% after years of losses
Market penetration expanding to type 2 diabetes from core type 1 market

This framework sees clear late innings — growth decelerating while margins peak typically marks the end of the easy gains. The shift from growth to profitability optimization confirms the story has matured.

Operating Margin
THE INSTITUTIONAL FOOTPRINTsaturated

Is this overowned by the big money?

Institutional ownership at 94.6%, up from 93.98%
159 new institutional positions opened in last 4 quarters
Average holding period of 48.7 years in top 10 holders
Analyst targets range from $72-$95 with $85.82 consensus

Lynch would run from this — 94.6% institutional ownership leaves almost no room for new buyers. The framework sees maximum saturation, exactly what Lynch avoided in his search for undiscovered opportunities.

Price Targets
72.0
low
95.0
high
87.0
median
85.8
consensus
KEY NUMBERS
VERDICT

Applying the Lynch framework reveals an uncomfortable truth — DexCom transformed from fast grower to profitable stalwart precisely when the market still prices it like a growth story. The 4.2% revenue growth makes the 24x P/E ratio unjustifiable through this lens, despite record margins and insider buying. Lynch taught that great companies become poor investments when growth slows but valuation remains elevated. Would Lynch rather own a boring company growing steadily at 4% and trading at 10x earnings?

This analysis applies Peter Lynch's published investment framework to publicly available financial data. It is not authored by, endorsed by, or affiliated with Peter Lynch. Educational purposes only. Not financial advice.

OTHER PERSPECTIVES
Benjamin Graham framework
The Value Architect
Bullish
Warren Buffett framework
The Owner-Operator
Bullish
Howard Marks framework
The Cycle Whisperer
Bullish
Michael Mauboussin framework
The Expectations Engineer
Leaning Bullish
Explore
Verisk Analytics, Inc.VRSKLinde plcLINGE HealthCare Technologies Inc.GEHCMondelez International, Inc.MDLZCintas CorporationCTASVertex Pharmaceuticals IncorporatedVRTX
EDUCATIONAL ONLY · NOT FINANCIAL ADVICEv2